MGC Pharma flags restructure in face of ‘dire alternatives’

MGC Pharmaceuticals has flagged a restructure to shareholders in a bid to secure its future in the face of “dire alternatives”.

Managing director Roby Zomer told investors despite “material operational achievements”, the firm faced a “critical financial juncture” in the wake of underwhelming fundraising efforts and a falling share price.